EPCAM and breast carcinoma: Analysis of breast cancer patient blood by RareCyte technology revealed the clear presence of cCTCs (EpCAM+, PanCK+, CD45- cells, Figure 1a) as well as the presence of T2CTCs (Figure 1b,c).